InflaRx is cutting approximately 30% of its employees in a bid to streamline its spending and pour more of its resources into its lead candidate. To accompany the layoffs, InflaRx will also pull money from its investigational antibody Gohibic, according to a press announcement Jan. 8.
All entries for: InflaRx
January 12, 2026
InflaRx
Discontinued Research, Layoffs
Jena, Germany
51-200 employees
Disease Area: Chronic Disease, Immune Diseases, Infectious Diseases
Drug Type: Biologic, Small Molecule